Genetic basis of cannabis use: a systematic review

Alannah Hillmer¹, Caroul Chawar¹, Stephanie Sanger², Alessia D’Elia¹, Mehreen Butt³, Raveena Kapoor⁴, Flavio Kapczinski¹, Lehana Thabane⁵ and Zainab Samaan¹*

Abstract

Background: With the increase in cannabis use rates, cannabis use disorder is being reported as one of the most common drug use disorders globally. Cannabis use has several known physical, psychological, and social adverse events, such as altered judgement, poor educational outcomes, and respiratory symptoms. The propensity for taking cannabis and the development of a cannabis use disorder may be genetically influenced for some individuals. Heritability estimates suggest a genetic basis for cannabis use, and several genome-wide association studies (GWASs) have identified possible regions of association, albeit with inconsistent findings. This systematic review aims to summarize the findings from GWASs investigating cannabis use and cannabis use disorder.

Methods: This systematic review incorporates articles that have performed a GWAS investigating cannabis use or cannabis use disorder. MEDLINE, Web of Science, EMBASE, CINAHL, GWAS Catalog, GWAS Central, and NIH Database of Genotype and Phenotype were searched using a comprehensive search strategy. All studies were screened in duplicate, and the quality of evidence was assessed using the quality of genetic association studies (Q-Genie) tool. All studies underwent qualitative synthesis; however, quantitative analysis was not feasible.

Results: Our search identified 5984 articles. Six studies met our eligibility criteria and were included in this review. All six studies reported results that met our significance threshold of \( p \leq 1.0 \times 10^{-7} \). In total 96 genetic variants were identified. While meta-analysis was not possible, this review identified the following genes, ANKFN1, INTS7, PI4K2B, CSMD1, CST7, ACSS1, and SCN9A, to be associated with cannabis use. These regions were previously reported in different mental health conditions, however not in relation to cannabis use.

Conclusion: This systematic review summarized GWAS findings within the field of cannabis research. While a meta-analysis was not possible, the summary of findings serves to inform future candidate gene studies and replication efforts.

Systematic Review Registration PROSPERO CRD42020176016.

Keywords: Systematic review, Cannabis, Genetics, Genome-wide Association Study

Introduction

Rationale

Over the past two decades cannabis use and dependence are estimated to have increased, with cannabis use disorder (CUD) reported as one of the most common drug use disorders globally [1]. In Canada, it has been reported that nearly 17 percent of Canadians aged 15 years and older reported using cannabis between
October and December of 2019, an increase from 14 percent between January to March of 2018. Additionally, cannabis consumption rates are higher among males than females [2]. Concerningly, cannabis has been associated with substantial adverse effects. Like other drugs, cannabis can result in cravings, dependence, and drug-seeking behaviour [3, 4]. During intoxication, cannabis can interfere with memory, motor coordination, altered judgement, and at higher doses, paranoia or psychosis [3]. Further, repeated use of cannabis can have long-lasting effects, including altered brain development, poor education outcome, cognitive impairment, diminished life satisfaction and achievement, poor professional and social achievements, symptoms of chronic bronchitis and increased risk of chronic psychiatric disorders [3, 5].

Heritability estimates for cannabis use initiation varied from 30 to 48%, and from 51 to 59% for problematic cannabis use, suggesting a genetic component exists [6]. Genome-wide association study (GWAS) meta-analyses have identified possible regions of association on chromosome 3 for lifetime cannabis use (CADM2), chromosome 10 for CUD (rs77300175), and chromosome 16 for age of first cannabis use (ATP2C2) [7–9]. Moreover, candidate gene studies have detected some significant associations with cannabis use on the CNR1, GABRA2, FAAH, and ABCB1 genes, but as with genome-wide association studies (GWASs), replication of these associations has been inconsistent [10].

GWASs provide a ‘hypothesis-free’ method of identifying novel variant-trait associations, leading to the discovery of novel biological mechanisms and diverse clinical applications [11]. As such, in this systematic review, we will summarize GWAS findings relevant to cannabis use or CUD outcomes and discuss future directions.

Objectives:
The main goal of this systematic review is to identify genetic variants from GWASs associated with cannabis use.

Primary objectives of this systematic review include the following:

1. Identify genetic variants associated with current cannabis use. Current cannabis use is defined by either self-report or positive urine drug screens within 1 month of the study being conducted.
2. Identify genetic variants associated with lifetime cannabis use. Lifetime cannabis use is defined by any self-reported or positive urine drug screens of cannabis use within one’s lifetime.
3. Identify genetic variants associated with CUD. CUD is defined by any diagnostic and classification systems used to diagnose CUD or questionnaires validated to assess CUD.

Secondary objectives of this systematic review include the following:

1. Identify genetic variants associated with the adverse outcomes of cannabis use, including psychiatric (cognitive impairment, psychotic symptoms, depression, anxiety, suicidal behavior) and non-psychiatric (chronic bronchitis, lung infections, chronic cough, increased risk of motor vehicle accidents) [12–14].
2. When feasible, perform subgroup summaries by sex or ethnic differences.

Methods
This systematic review is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [15] (see PRISMA checklist in Additional file 1). The Human Genome Epidemiology Network (HuGENet) guideline was used to supplement the PRISMA guideline. While this review does not conform with the HuGENet guideline expectations of reporting on candidate gene study findings, the HuGENet is used to uphold the standard of reporting research specific to genetic association studies [16].

Protocol and registration
The protocol for this systematic review has been registered within the International Prospective Register of Systematic Reviews (PROSPERO) (registration number: CRD42020176016) [17]. The full protocol has been published in the journal of Systematic Reviews [18].

Eligibility criteria
This review investigates GWASs presenting original data on associations between cannabis use and genetic polymorphisms using any study design (i.e. case–control, cohort, etc.). We include studies investigating CUD as well as any studies measuring any use of cannabis. Studies that investigated CUD as defined by any version of the Diagnostic and Statistical Manual (DSM) or other diagnostic and classification systems such as the International Statistical Classification of Diseases and Related Health Problems–10 (ICD-10) were included. We define cannabis use based on the included studies’ definitions and accept the following definitions: current cannabis use is defined as either self-report or positive urine drug screens within one month of the study being conducted, and lifetime cannabis use is defined as any self-reported or positive urine drug screens of cannabis use within one’s lifetime [19]. All other studies that did not perform a GWAS and investigate cannabis use or CUD were excluded. No restrictions were placed on the study setting or participant’s age, sex, ethnic background or
language. Further details on the inclusion criteria can be found in the study protocol [18].

**Information sources and search strategy**

A Health Science Librarian was consulted to develop a comprehensive search strategy. OVID MEDLINE 1946-Present, Web of Science 1976-Present, OVID EMBASE 1974-Present, EBSCOHost CINHAL 1981-Present, GWAS Catalog, GWAS Central, and NIH Database of Genotype and Phenotype databases were searched using the established strategy, modified for each database. All databases were searched from inception to February 2nd, 2021. The search strategy included all terms relevant to genome-wide association studies and cannabis. The search strategies for each electronic database are provided in Table 1.

**Study selection and data collection process**

Calibration was completed prior to the formal screening process. Title and abstract screening, full-text screening and data extraction phases were completed in duplicate through Covidence [20]. Conflict resolution at the title and abstract and full-text stages was performed by a senior reviewer (AH or CC), blind to the reviewer’s vote. Disagreements at the data extraction stage was resolved by the consensuses of the two reviewers. The reason for study exclusion was recorded at the full-text stage.

**Data items**

Data extracted included baseline participant characteristics, the measure of cannabis used, relevant and significant measured outcomes, statistical measures, and reported study limitations and conflicts. For this review, the threshold of significance of genetic variants reaching \( p \leq 10^{-7} \) was set, as some GWAS results with this significance level have been shown to be replicable within the literature [21].

**Risk of bias within studies and data analysis**

Quality assessment was completed in duplicate for each included study using the Quality of Genetic Association Studies (Q-Genie) tool [Version 1.1] [22]. Disagreements of quality assessment was resolved through discussion between the two reviewers, and the first author reviewed and confirmed all quality assessments.

**Summary measures and synthesis of results**

A random-effects meta-analysis through pooled odds ratios was planned to quantitatively assess the data. However, these measures were not appropriate as data extracted from each study were unique and could not be combined. For the aforementioned reasons, a heterogeneity test, and a subgroup meta-analyses could not be completed.

**Risk of bias across studies**

The Grading of Recommendations Assessment, Development and Evaluation (GRADE) was used to assess the strength of evidence, with specific consideration of prognostic factors [23, 24]. GRADE scores assess outcomes according to the risk of bias, publication bias, consistency, directness, and precision [23].

**Results**

**Study selection**

The search strategy, along with hand-searching, yielded 5984 studies. After removing duplicates through the Zotero reference manger and Covidence, 4344 studies were unique and screened for eligibility at the title and abstract phase [20, 25]. Of the 69 studies eligible for full-text screening, 6 studies were included in this review and underwent data extraction and quality assessment.

Studies frequently failed to meet the eligibility criteria for inclusion for the following reasons (i) conducted a GWAS meta-analysis, (ii) conducted a candidate gene study or (iii) were investigating a factor associated with cannabis use (i.e. aggression) rather than cannabis use itself.

Please see the PRISMA flow diagram in Fig. 1.

**Study characteristics**

Individual study characteristics are reported in Table 2. Two studies were case–control, two were cohort, one was case-cohort, and another was case-cohort and cohort. Interestingly, the first GWAS in the field of cannabis use was published in 2011 and the most recent conducted in 2019 [26, 27]. All studies used data from large study datasets. Three studies utilized the Study of Addiction: Genetics and Environment (SAGE) [4, 26, 28]. The International Cannabis Consortium (ICC), UKBiobank, and 23andMe were utilized in one study which performed three independent GWAS on the aforementioned datasets [9]. Another study combined the Yale-Penn and the International Consortium on the Genetics of Heroin Dependence (ICGHD) to perform a single GWAS [4]. Finally, one study utilized the Integrative Psychiatric Research (iPSYCH) [27] and another the Netherlands twin registry [29]. Studies varied in size from 3053 to 51,372 participants. Of the studies which reported participants’ sex and age, three studies had a population comprised of mostly female participants [9, 26, 28, 29], while only one reported majority male [4]. The mean age of study participants varied from mid-thirties to mid-fifties. Three studies reported on participants of European or African American
| Table 1 | Search strategy |
|----------|----------------|
| **OVID MEDLINE** | 1. Genome-Wide Association Study/ 2. Genotyping Techniques/ 3. Genome, Human/ 4. Genetic Variation/ 5. genetics/ or exp human genetics/ 6. (human* adj2 (genotyp* or genome* or genetic*)).ti,ab,kw,kf 7. (GWS or GWAS or GWA).mp 8. genome wide.ti,ab,kw,kf 9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 10. exp Cannabis/ 11. ((cannabis* or marijuana* or cannabinoids* or marihuana* or hash* or kush* or weed* or pot* or THC* or CBD*) adj2 (overdose* or use* or using or misuse* or abus* or dependence* or addict*)).ti,ab,kw,kf 12. 10 or 11 13. 9 and 12 14. Limit 13 to humans |
| **Web of Science** | T5 = (genome-wide association study or genome-wide association or GWAS or GWA or genome wide) T5 = (human NEAR/2 genome or (cannabis* or marijuana* or cannabinoids* or marihuana* or hash* or kush* or weed* or pot* or THC* or CBD*) NEAR/2 (overdose* or use* or using or misuse* or abus* or dependence* or addict*)) T5 = (cannabis* or marijuana* or marihuana*) 10 or 11 9 and 12 Limit 13 to human |
| **OVID EMBASE** | Genome-Wide Association Study/ Genotyping Techniques/ Genome, Human/ Genetic Variation/ genetics/ or exp human genetics/ (human* adj2 (genotyp* or genome* or genetic*)).ti,ab,kw. (GWS or GWAS or GWA).mp. genome wide.ti,ab,kw. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 exp Cannabis/ ((cannabis* or marijuana* or cannabinoids* or marihuana* or hash* or kush* or weed* or pot* or THC* or CBD*) adj2 (overdose* or use* or using or misuse* or abus* or dependence* or addict*)).ti,ab,kw. 10 or 11 9 and 12 Limit 13 to human |
| **EBSCOHost CINAHL** | genome-wide association study or genome-wide association or GWAS or GWA or genome wide or genome cannabis* or marijuana* or cannabinoids* or marihuana* or hash* or kush* or weed* or pot* or THC* or CBD*) overdose* or use* or using or misuse* or abus* or dependence* or addict* S2 and S3 S1 and S4 Limit to Human |
| **GWAS Catalog** | Terms Searched: Cannabis Dependence Marihuana Marijuana Cannabinoids Hash Kush Weed Pot THC CBD |
ethnicities [4, 26, 28] and three studies reported a European only ethnicity [9, 27, 29]. Reported outcomes of interest included lifetime cannabis use [8, 9], CUD as defined by either the DSM-IV [26] or ICD-10 [27], CUD criteria count [4, 28] or age of onset of cannabis use [29].

Risk of bias within studies
The Q-Genie tool [version 1.1] was completed in duplicate and used to assess study quality. Studies were assessed on a scale of 1 to 7 for 11 items. An overall score greater than or equal to 45 for studies with a control group and studies with an overall score greater than 40 without a control group were considered good quality according to the Q-Genie tool [22]. All studies were considered to be good quality except for one study, Minica et al., which was deemed moderate quality. It should be noted that Minica et al. did not discuss any potential sources of bias or limitations within their study. Additionally, the study was conducted using the Netherlands twin registry and while individuals with a genetic relatedness larger than 0.025 were excluded for some analyses, heritability was not accounted for in all analyses and may therefore introduce bias [29]. Three studies reported potential conflicts of interest due to involvement with industry funding [4, 26, 28], two studies report conflict in a patent involved in identifying SNPs associated with addiction [26, 28] and one study reports authors are employees of deCODE genetics [27]. Please see Table 3 for the studies Q-genie scores of the included studies.

Results of individual studies
All six studies included in this systematic review reported outcomes that reached the significance threshold set a priori (Table 4).

Agrawal et al. [26] identified two SNPs associated with DSM-IV cannabis dependence within the ANKFN1 gene (chromosome 17). European and African American participants were selected from the SAGE study which was aimed to primarily study DSM-IV alcohol dependence. Case status was defined as a lifetime history of DSM-IV cannabis dependence, with controls defined as using cannabis at least once in their lifetime but not meeting criteria for DSM-IV cannabis dependence.

Agrawal et al. [28] identified a SNP reaching borderline significance threshold on chromosome 3 associated with CUD factor scores in African Americans, however, no associated gene was identified. Participants were European and African Americans selected from the SAGE study. DSM factor scores were developed from 12 DSM-IV and DSM-5 criteria for CUD.

Demontis et al. [27] identified 26 SNPs associated with CUD on chromosome 8, with no associated gene identified. However, only 5 SNPs were discussed and identified in the paper, and thus only 5 SNPs are reported in this review. Participants were selected from the iPSYCH cohort and were of European ancestry. The iPSYCH cohort was established to study six major psychiatric disorders, however, identified participants meeting ICD-10 CUD [27].

Minica et al. reported 3 SNPs associated with cannabis initiation and 24 SNPs associated with the age of...
onset of cannabis use. Identified SNPs were found on chromosomes 5, 9, 18 and 19, with one SNP associated with cannabis initiation was found on the Zinc finger protein, \textit{ZNF181}. All participants were of European descent and were selected from the Netherlands Twin Registry. Cannabis initiation was defined as ever/never having used cannabis while age of onset was determined by asking participants an open-ended question [29].

Pasman et al. conducted three independent GWASs in three separate cohorts, all of which included European participants: ICC, UKBiobank, and 23andMe. While results from 23andMe were unable to be shared due to privacy policies, the lead author kindly provided SNPs reaching borderline significance threshold with lifetime cannabis use for GWAS conducted in the ICC and UKBiobank cohort. One SNP in the ICC cohort and 18 SNPs in the UKBiobank were associated with lifetime cannabis use, with no genes specified in either. Lifetime cannabis use was defined as any cannabis use during lifetime [9].

Sherva et al. identified 42 SNPs associated with DSM-IV cannabis dependence criteria count across 27 different genes/regions including \textit{INTS7}, \textit{SNORA26}, \textit{RPS20P10}, \textit{PI4K2B}, \textit{CSMD1}, \textit{PSMB7}, \textit{HABP2}, \textit{MEFV}, \textit{CST7}, \textit{APMAP}, \textit{ACSS1}, \textit{snoU13}, \textit{TPST2}, \textit{SCN9A}, \textit{CTA-445C9.15}, \textit{CTA-445C9.14-CTA-4}, \textit{SCN9A-SCN7A}, \textit{ARL2BPP5-RP11-541P9.3}, \textit{RP11-755E23.3-CCDC67}, \textit{SNORD11-RNU6-1014P}, \textit{RP5-860P4.2-CST7}, \textit{RNU6-1257P}, \textit{APMAP-ACSS1}, \textit{C9.15}, \textit{RPS20P10-CYP26B1}, \textit{PI4K2B-ZCCHC4}, and \textit{CST7-APMAP}. European and African American participants were selected from the Yale-Penn Study, the SAGE study and the ICGHD cohorts [4].
| First Author Last Name, Year | Title of Publication | Study Design | Cohort used | Sample Size | % Male | Mean age | Ethnicity | Outcome of interest |
|-----------------------------|----------------------|--------------|-------------|-------------|--------|----------|-----------|------------------|
| Agrawal, 2011              | A Genome-wide Associa- tion Study of DSM-IV Cannabis Dependence | Case–Control | SAGE        | 3054        | NR     | 39.00    | 2019 European-Americans, 1035 African Americans | Life-time history of DSM-IV cannabis dependence, modified to included cannabis withdrawal |
| Agrawal, 2014              | DSM-5 Cannabis Use Disorder: A Phenotypic and Genomic Perspective | Case–control | SAGE        | 3053        | 49%    | 38.10    | 2018 European-Americans, 1035 African Americans | DSM-5 cannabis use disorder factor scores |
| Demontis, 2019             | Genome-wide association study implicates CHRNA2 in cannabis use disorder | Case-cohort  | iPSYCH      | CUD: 2387 Control: 48,985 Total: 51,372 | NR      | CUD: 24.77 Control: 22.67 | European | International Statistical Classification of Disease and Related Health Problems, 10th revision (ICD-10) diagnosis reflecting problematic and persistent use of cannabis |
| Minica, 2015               | Heritability, SNP- and Gene-Based Analyses of Cannabis Use Initiation and Age at Onset | Cohort       | Netherlands twin registry | 6744 | 39.1% | 39.09 | European | Self-reported use of cannabis ever in lifetime and self-reported age of onset of cannabis use |
| Pasman, 2018               | GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal effect of schizophrenia liability | Cohort       | ICC study   | 35,297 | 44.3% | 35.7 | European | Any cannabis use within lifetime |
| Sherva, 2016               | Genome-wide Association Study of Cannabis Dependence Severity, Novel Risk Variants, and Shared Genetic Risks | Cohort/Case-cohort | Yale-Penn, SAGE, ICGHD | 14,754 | 53.4% | 39.24 | 8754 European-American, 6000 African American | Criterion count for DSM-IV Cannabis Dependence |
| First Author Last Name, Year | Reported conflicts of interest | Reported study limitations | Q-Genie Score | Quality Assessment |
|-------------------------------|---------------------------------|---------------------------|---------------|-------------------|
| Agrawal, 2011                | Drs. LJ Bierut, J. Rice, A. Goate and S. Saccone are listed as inventors on the patent “Markers for Addiction” (US 20,070,258,898): covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction. Dr. Bierut has acted as a consultant for Pfizer Inc. in 2008. All other authors report no competing interests | SAGE study was ascertained for alcohol dependence led to a high level of comorbidity in the cannabis dependent cases and exposed controls. Use of controls with other forms of substance dependence but not cannabis dependence protected against signals that may have been less specific. Power computations revealed that minor allele frequencies ranging from 15–40% association signals with odds ratio exceeding 1.45 were able to be detected. | 53 | Good Quality |
| Agrawal, 2014                | Laura J. Bierut is listed as an inventor on issued U.S. Patent 8,080,371, “Markers for Addiction” covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction. | The sample was ascertained from three family studies of substance use disorders for the express purpose of identifying genetic variants for alcoholism, nicotine and cocaine dependence and related pathology. Differences in DSM-IV and DSM-5 criteria leading to different assessments of withdrawal and diagnosis of CUD across study populations. | 55 | Good quality |
| Demontis, 2019               | T. Werge has been a lecturer and advisor to H. Lundbeck A/S. T.E. Thorgersson, D.F. Gudbjartsson, G.W. Reginsson, H. Stefansson and K. Stefansson are employees of deCODE genetics/Amgen. None reported. | No statistically significant GWAS findings that pass the threshold p < 1.0 × 10^{-8}. | 57 | Good quality |
| Minica, 2015                 | None | Lifetime cannabis was analyzed as a single dichotomous measure combining experimental and regular users in a single group. The power of some analyses may have been limited. | 49 | Moderate quality |
| Pasman, 2018                 | P.F., S.L.E. and members of the 23andMe Research Team are employees of 23andMe Inc. J.A.R.Q. was on the speakers bureau and/or acted as consultant for Eli Lilly, Janssen-Clag, Novartis, Shire, Lundbeck, Almirall, BRAINGAZE, Sinclairlab and Rubió in the last 5 years. He also received travel awards (air tickets and hotel) for taking part in psychiatric meetings from Janssen-Clag, Rubió, Shire and Eli Lilly. The Department of Psychiatry chaired by him received unrestricted educational and research support from the following pharmaceutical companies in the last 5 years: Eli Lilly, Lundbeck, Janssen-Clag, Actelion, Shire, Ferrer and Rubió. | 52 | Good quality |
| First Author Last Name, Year | Reported conflicts of interest | Reported study limitations | Q-Genie Score | Quality Assessment |
|-----------------------------|--------------------------------|---------------------------|--------------|--------------------|
| Sherva, 2016                | Dr Kranzler reports being a consultant or an advisory board member for Alkermes, Indivior, Lundbeck, and Otsuka (unrelated to the present study) and being a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which is supported by AbbVie, Elysium, Lilly, Lundbeck, and Pfizer. No other disclosures were reported. | One of the significant SNPs identified (rs143244591 on chromosome 3) has little supportive evidence for association from other SNPs in the region. None of the GWAS SNPs identified in the full GWAS analysis are rare. Lack of evidence of associations in both the European American and African American participants. The Yale-Penn samples who underwent genotyping on the HumanOmni1-Quad and Human Core Exome chips showed more consistent results than the corresponding SAGE population. The cohorts used have higher rates of polysubstance dependence than the general population and may not be generalizable to individuals who only use cannabis. | 52 | Good quality |
| First Author | Outcome associated with SNP | Build | SNP IDs | ChrPos | Alleles Minor Allele | Gene or Locus | MAF | N | Measure of Association type | Measure of Association value | Measure of Variability | Measure of Variability value | p value | Ethnicity |
|-------------|-----------------------------|-------|---------|--------|----------------------|---------------|-----|---|---------------------------|--------------------------|------------------|-----------------------------|---------|-----------|
| Agrawal, DSM-IV cannabis dependence 2011 | | hg18 | rs1019238 | 17 | ANKFN1 | EA = 0.4, AA = 0.1 | 3054 | OR | 1.453 | 95% CI 1.254–1.682 | 6.1E–07 | AA & EA |
| Agrawal, Cannabis use disorder factor scores from 12 DSM IV + 5 criteria 2014 | | hg18 | rs4364205 | 3 | T | 0.41 | 1035 | β | −0.19 | 95% CI −0.26− (−0.12) | 1.3E−07 | AA |
| Demonetis, Cannabis use disorder 2019 | | hg19 | rs56372821 | 8 | A/G | A | 0.163 | 51,372 | OR | 0.728 | | 9.31E−12 | EA |
| Minica, Cannabis initiation 2015 | | GRCh37 | rs35487050 | 19:35,221,228 | C/T | ZNF181 | 6744 | β | 0.81 | SE 0.16 | 1.68E–07 | E |
| | | | rs35917943 | 19:35,147,183 | C/A | | < 0.05 | 6744 | β | 0.77 | SE 0.15 | 1.62E–07 | E |
| | | | rs35760174 | 19:35,221,582 | A/C | | 0.11 | 51,372 | OR | 0.702 | | 7.41E−08 | EA |
| | | | rs357220 | 8 | A/G | A | 0.259 | 51,372 | OR | 0.8258 | | 2.46E–07 | EA |
| | | | rs35487050 | 19:35,221,228 | C/T | ZNF181 | 6744 | β | 0.81 | SE 0.16 | 1.68E–07 | E |
| | | | rs78505392 | 5:95,422,966 | C/G | | < 0.05 | 5148 | β | 0.58 | SE 0.1 | 2.16E–07 | E |
| | | | rs12003072 | 9:86,771,161 | A/C | | 5.148 | β | 0.52 | SE 0.09 | 3.04E–07 | E |
| | | | rs77097806 | 5:95,456,735 | A/G | | 5.148 | β | 0.56 | SE 0.1 | 3.54E–07 | E |
| | | | rs6879664 | 5:95,400,187 | A/G | | 5.148 | β | 0.57 | SE 0.1 | 3.61E–07 | E |
| | | | rs4613744 | 5:95,451,494 | C/T | | 5.148 | β | 0.55 | SE 0.1 | 5.07E–07 | E |
| | | | rs90218730 | 5:95,492,765 | G/T | | 5.148 | β | 0.59 | SE 0.11 | 5.98E–07 | E |
| | | | rs74305417 | 9:86,779,774 | C/G | | 5.148 | β | 0.52 | SE 0.09 | 6.2E–07 | E |
| | | | rs142981069 | 18:58,820,22 | G/A | | 5.148 | β | 0.47 | SE 0.09 | 7.25E–07 | E |
| | | | rs12386084 | 18:58,827,145 | C/G | | 5.148 | β | 0.47 | SE 0.09 | 7.25E–07 | E |
| First Author Last Name, Year | Outcome associated with SNP | Build SNP IDs | Chr:Pos | Alleles | Minor Allele | Gene or Locus | MAF | N | Measure of Association type | Measure of Association value | Measure of Variability | Measure of Variability value | p value | Ethnicity |
|-------------------------------|----------------------------|---------------|---------|---------|--------------|--------------|------|---|-----------------------------|-----------------------------|--------------------------|-----------------------------|------|-----------|
| rs117918936 18:58,828,323    | G/A                       |               |         |         |              |              |      | 5148 | β                           | 0.47                         | SE                       | 0.09                         | 7.25E−07 | E         |
| rs2160801 18:58,829,024      | T/A                       |               |         |         |              |              |      | 5148 | β                           | 0.47                         | SE                       | 0.09                         | 7.25E−07 | E         |
| rs14542173 18:58,829,597     | T/C                       |               |         |         |              |              |      | 5148 | β                           | 0.47                         | SE                       | 0.09                         | 7.25E−07 | E         |
| rs117538409 18:58,830,942    | G/C                       |               |         |         |              |              |      | 5148 | β                           | 0.47                         | SE                       | 0.09                         | 7.25E−07 | E         |
| rs17817245 18:58,832,135     | A/G                       |               |         |         |              |              |      | 5148 | β                           | 0.47                         | SE                       | 0.09                         | 7.25E−07 | E         |
| rs140206009 18:58,833,215    | A/G                       |               |         |         |              |              |      | 5148 | β                           | 0.47                         | SE                       | 0.09                         | 7.25E−07 | E         |
| rs117692712 18:58,834,506    | T/G                       |               |         |         |              |              |      | 5148 | β                           | 0.47                         | SE                       | 0.09                         | 7.25E−07 | E         |
| rs17817423 18:58,835,462     | C/T                       |               |         |         |              |              |      | 5148 | β                           | 0.47                         | SE                       | 0.09                         | 7.25E−07 | E         |
| rs97923608 9:86,782,955      | C/A                       |               |         |         |              |              |      | 5148 | β                           | 0.5                          | SE                       | 0.09                         | 9.09E−07 | E         |
| rs78456402 4:36,781,000      | G/A                       |               |         |         |              |              |      | 5148 | β                           | 0.5                          | SE                       | 0.09                         | 9.09E−07 | E         |
| rs79236038 9:86,781,000      | A/G                       |               |         |         |              |              |      | 5148 | β                           | 0.5                          | SE                       | 0.09                         | 9.09E−07 | E         |
| rs11999891 9:86,783,107      | T/C                       |               |         |         |              |              |      | 5148 | β                           | 0.5                          | SE                       | 0.09                         | 9.09E−07 | E         |
| rs11214441 11:11,246,913     | T/A                       |               |         |         |              |              |      | 5148 | β                           | 0.5                          | SE                       | 0.09                         | 9.09E−07 | E         |
| rs11214441 11:11,246,913     | T/A                       |               |         |         |              |              |      | 5148 | β                           | 0.5                          | SE                       | 0.09                         | 9.09E−07 | E         |
| rs11214441 11:11,246,913     | T/A                       |               |         |         |              |              |      | 5148 | β                           | 0.5                          | SE                       | 0.09                         | 9.09E−07 | E         |
| rs87565656 7:148,048,453     | G/A                       |               |         |         |              |              |      | 5148 | β                           | 0.5                          | SE                       | 0.09                         | 9.09E−07 | E         |
| rs4099556 4:36,871,936       | G/A                       | MEIR801       |         |         |              |              |      | 5148 | β                           | 0.5                          | SE                       | 0.09                         | 9.09E−07 | E         |
| rs78680800 4:36,871,936      | G/A                       | MEIR801       |         |         |              |              |      | 5148 | β                           | 0.5                          | SE                       | 0.09                         | 9.09E−07 | E         |
| rs79710704 4:36,871,936      | G/A                       | MEIR801       |         |         |              |              |      | 5148 | β                           | 0.5                          | SE                       | 0.09                         | 9.09E−07 | E         |
| rs79565656 7:148,048,453     | G/A                       | MEIR801       |         |         |              |              |      | 5148 | β                           | 0.5                          | SE                       | 0.09                         | 9.09E−07 | E         |
| rs4083708 8:76,702,058       | G/A                       | MEIR801       |         |         |              |              |      | 5148 | β                           | 0.5                          | SE                       | 0.09                         | 9.09E−07 | E         |
| rs1186071 12:6,954,864       | G/A                       | MEIR801       |         |         |              |              |      | 5148 | β                           | 0.5                          | SE                       | 0.09                         | 9.09E−07 | E         |
| rs7444260 12:6,954,864       | G/A                       | MEIR801       |         |         |              |              |      | 5148 | β                           | 0.5                          | SE                       | 0.09                         | 9.09E−07 | E         |
| rs7444260 12:6,954,864       | G/A                       | MEIR801       |         |         |              |              |      | 5148 | β                           | 0.5                          | SE                       | 0.09                         | 9.09E−07 | E         |
| First Author | Last Name, Year | Outcome associated with SNP | Build | SNP IDs | Chr:Pos | Alleles | Minor Allele | Gene or Locus | MAF | N | Measure of Association type | Measure of Association value | Measure of Variability | Measure of Variability value | p value | Ethnicity |
|--------------|----------------|----------------------------|-------|---------|---------|---------|-------------|--------------|-----|---|--------------------------|---------------------------|------------------|-----------------------------|---------|-----------|
| Sherva, 2016 | DSM-IV cannabis dependence criteria count | rs4492854 | 11:112,983,534 | C/T | C | INTS7 | 0.4363 | 30,366 | β | 0.1113 | SE | 0.021251 | 1.63E−07 | E |
| rs141482228 | GROh37 | rs77448142 | 1:212,183,114 | - | 2.167,239,818 | INTS7 | 1250 | 1.250 | 8.84E−10 | AA |
| rs77323306 | | rs7332345 | 1250 | 7.61E−09 | AA |
| rs7832545 | | rs77378271 | 2640 | 3.61E−10 | EA |
| rs75721860 | | rs7853028 | 2640 | 7.12E−10 | EA |
| rs9469311 | | rs116474042 | 4750 | 4.63E−07 | EA |
| rs1189167038 | | rs1891670415 | 1250 | 3.02E−07* | AA |
| rs114269992 | | rs117047810 | 4750 | 5.30E−10 | EA |
| rs11466037 | | rs117047810 | 1250 | 6.69E−07* | AA |
| rs183568578 | | rs11466037 | 1250 | 2.75E−09 | EA |
| rs114269992 | | rs117047810 | 1250 | 8.94E−09 | AA |
| rs11466037 | | rs117047810 | 1250 | 7.21E−07 | AA |
| rs183568578 | | rs11466037 | 1250 | 3.81E−07 | AA |
| rs114269992 | | rs117047810 | 1250 | 2.64E−09 | AA |
Table 4 (continued)

| First Author Last Name, Year | Outcome associated with SNP | Build SNP IDs | Chr:Pos | Alleles Minor Allele | Gene or Locus | MAF | N | Measure of Association type | Measure of Association value | Measure of Variability type | Measure of Variability value | p value | Ethnicity |
|-----------------------------|-----------------------------|---------------|---------|----------------------|---------------|-----|---|---------------------------|-----------------------------|-----------------------------|-----------------------------|---------|-----------|
| rs114620529                 |                             |               |         |                      |               |     | 1250 | 1.63E−07*                  | 2.15E−07                    | 1.6E−07                     |
| rs116629084                 |                             |               |         |                      |               |     | 1250 | 1.70E−07                    | 1.7E−07*                    | 1.2E−07*                     |
| rs115384512                 |                             |               |         |                      |               |     | 1250 | 8.91E−08                     | 8.91E−08                    | 7.19E−08*                   |
| rs147641662                 |                             |               |         |                      |               |     | 1250 | 8.87E−08                     | 8.87E−08                    | 7.19E−08*                   |
| rs191783144                 |                             |               |         |                      |               |     | 1250 | 8.81E−08                     | 8.81E−08                    | 7.07E−08*                   |
| rs146806338                 |                             |               |         |                      |               |     | 1250 | 8.73E−08                     | 8.73E−08                    | 7.03E−08*                   |
| rs114828727                 |                             |               |         |                      |               |     | 1250 | 6.92E−08                     | 6.92E−08                    | 6.52E−08*                   |
| rs114128002                 |                             |               |         |                      |               |     | 1250 | 9.01E−08                     | 9.01E−08                    | 9.01E−08*                   |
| rs115342711                 |                             |               |         |                      |               |     | 1250 | 2.54E−07                     | 2.54E−07                    | 2.54E−07*                   |
| rs115764440                 |                             |               |         |                      |               |     | 1250 | 2.33E−07                     | 2.33E−07                    | 2.33E−07*                   |
| rs116068335                 |                             |               |         |                      |               |     | 1250 | 9.15E−08                     | 9.15E−08                    | 9.15E−08*                   |
| rs114637142                 |                             |               |         |                      |               |     | 1250 | 1.06E−07                     | 1.06E−07                    | 1.06E−07*                   |
| rs113232742                 |                             |               |         |                      |               |     | 1250 | 8.82E−08                     | 8.82E−08                    | 8.82E−08*                   |
Table 4 (continued)

| First Author Last Name, Year | Outcome associated with SNP | Build | SNP IDs | Chr:Pos | Alleles | Minor Allele | Gene or Locus | MAF | N | Measure of Association type | Measure of Association value | Measure of Variability value | p value | Ethnicity |
|-----------------------------|-----------------------------|-------|---------|---------|---------|--------------|--------------|-----|---|----------------------------|-----------------------------|-----------------------------|---------|-----------|
| rs114199928                 |                             |       | G1255   |         | ACSS1   |              |              |     |   |                             |                             |                             | 8.42E−08 | AA        |
| rs114836364                 |                             |       |         | rs116669368 | ACSS1   |              |              |     |   |                             |                             |                             | 8.23E−08 | AA        |
| rs145379934                 |                             |       |         | rs143020225 | 2:167,214,714 | G/A | snoU13,SCN9A | 0.95 | 4750 |                             |                             |                             | 3.96E−08 | AA        |
| rs143020225                 |                             |       |         | chr22:26,917,069 | C9.15,TPST2,CTA-44SC9.1C-4 | 2640 |                             | 3.15E−10 | EA   |
| rs4149485                   |                             |       |         | chr22:26,917,069 | C9.15,TPST2,CTA-44SC9.1C-4 | 2640 |                             | 2.24E−10 | EA   |

* Adjusted for the DSM-IV criteria counts for alcohol, cocaine, and opioid dependence

AA = African American, EA = European American, E = European

Bold type indicates variants for which the p value reached genome-wide significance ($p \leq 5 \times 10^{-8}$)
While no SNPs were reported within the same region not allowing further quantitative analysis, several phenotypic similarities exist across studies. Interestingly, two studies found that educational attainment was negatively associated with CUD [26, 27] and a third found positive genetic correlations with educational attainment [9]. Two studies found that cannabis dependence was significantly related to alcohol, nicotine, and cocaine dependence [4, 26] with a third reporting a positive genetic correlation between lifetime cannabis use and smoking and alcohol use and dependence [9].

Risk of bias across studies
Outcomes assessed for GRADE include lifetime cannabis use, diagnosis of CUD, criterion count for CUD and age of onset of cannabis use. All outcomes included two studies except for age of onset of cannabis use which only included one study. The full GRADE table can be found in Table 5. All outcomes were rates as important, and no outcome was rated as having a “very serious” concern pertaining to any certainty criteria. Only the outcomes of diagnosis of CUD and criterion count for CUD had a serious rating, both of which were in the category of indirectness. Both of these outcomes were downgraded due to the use of different diagnostic criteria. More specifically, for the outcome of diagnosis of CUD Agrawal et al. [26] utilized the DSM-IV and Demontis et al. (2019) utilized the ICD-10 and for the outcome of criterion count of CUD Sherva et al. [4] utilized the DSM-IV criteria and Agrawal et al. [28] utilized a combination of DSM-IV and DSM-5 criteria.

Discussion
Summary of evidence
In this review we identified 96 genetic variants to be associated with different measures of cannabis. Of these genetic variants, 18 reached the genome-wide significance threshold of \( p \leq 5 \times 10^{-8} \), all of which are available in Table 4. As no genetic variants included in this review were reported in more than one study, meta-analyses were not possible. However, of the genetic variants identified in this review, several are located on genes in which previous studies have reported associations with mental health, namely ANKFN1, INTS7, PI4K2B, CSMD1, CST7, ACSS1, and SCN9A. ACSS1 catalyzes the synthesis of acetyl-CoA and has been associated with performance on standardized cognitive tests and bitter alcoholic beverage consumption [31–33]. SCN9A mediates the voltage-dependent sodium ion permeability of excitable membranes and plays a role in pain mechanisms, especially in the development of inflammatory pain [31]. As it is known that cannabis can have a negative impact on learning, memory and chronic bronchitis, known relation to mental illness and suggested role in pain management, these regions may have implications in cannabis use despite having no clear known biological relevance [3, 19].

Additionally, it is also important to highlight that genes identified in this review associated with cannabis use or CUD have also been associated with other neuropsychiatric disorders namely nicotine dependence, ADHD, bipolar disorder, schizophrenia, and alcohol
### Table 5  GRADE Assessment

| Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Effect | Certainty | Importance |
|--------------|--------------|---------------|--------------|-------------|----------------------|--------|-----------|------------|
|              | No of events | No of individuals | Rate (95% CI) |             |                      |        |           |            |
| **Cannabis use in lifetime** | 2 | Observational studies | Not serious | Not serious | Not serious | – | IMPORTANT |            |
| **Diagnosis of cannabis use disorder** | 2 | Observational studies | Not serious | Not serious | Serious a | Not serious | – | IMPORTANT |            |
| **Criterion count of cannabis use disorder** | 2 | Observational studies | Not serious | Not serious | Serious a | Not serious | – | IMPORTANT |            |
| **Age of onset of cannabis use** | 1 | Observational studies | Not serious | Not serious | Not serious | – | – | IMPORTANT |            |

*a* Different diagnostic classification
consumption suggesting that the genetic risk for the development of these disorders may not be independent. Previously genetic associations have been found amongst schizophrenia, bipolar disorder, ADHD, depression, and autism spectrum disorder, with a high genetic correlation between schizophrenia and bipolar disorder and a moderate correlation between ADHD and depression, ADHD and autism spectrum disorder, and ADHD and depression [34]. A recent GWAS meta-analysis added to the evidence on shared genetic associations amongst neuropsychiatric disorders by identifying that an increased risk of cannabis use disorder is genetically correlated with increased liability for smoking initiation, alcohol use, nicotine dependence, and psychiatric disorders (e.g. ADHD, schizophrenia, major depression) [35]. These genetic correlations among neuropsychiatric disorders, including cannabis, could reflect genuine pleiotropy or could indicate these psychiatric disorders, including CUD, are not completely independent [34, 35]. As such, it is important to discuss the biological and individual factors that influence the development of neuropsychiatric disorders.

Neuropsychiatric disorders are influenced by a range of factors, including genetics, personality/mood characteristics, psychological status, behaviour, neurocognitive functioning, and demographic characteristics [36, 37]. To begin, non-specific to CUD, the prenatal environment, including prenatal nutrition, maternal stress, and maternal substance abuse, can impact brain development and therefore the behavioural outcome of children. Potential mechanisms through which the prenatal environment can impact brain development occurs on multiple levels including genetic selection, epigenetic modification, mediation of brain-immune communications, abnormal metabolism pathways, synthetic mediation of hormones and the hypothalamic–pituitary–adrenal axis, and mediation of the microbiota-gut brain axis [37]. Furthermore, nutritional deficiency during critical stages of pregnancy has been linked to emotional and behavioural problems in children including decreased attention, decreased IQ, language delay, and neurodevelopment and related neuropsychiatric disorders [37–39]. More specifically, prenatal malnutrition has been linked to an increased risk of schizophrenia during the 1944–1945 Dutch Hunger Winter and the 1959–1961 Chinese famine. Additionally, a “U” relationship between serum 12(OH)D concentration and emotion, behaviour and attention has been found [38, 40]. Interestingly, the hippocampus, which plays an important role in learning and memory, has been suggested to be sensitive to the exposure of prenatal nutrition deficiency [39, 41]. The hippocampus has also been proven to be crucial in the pathophysiology of many neuropsychiatric disorders, in which the changes result from alerted brain development [41]. Maternal stress has been associated with poor offspring outcomes including cognition, health and educational attainment, however methodological challenges exist leading to potential misattribution of socially mediated (i.e. postnatal parenting) mechanisms to biological ones (i.e. alterations to developing fetal brain) [42, 43]. Finally, prenatal exposure to alcohol and other substances has been increasingly common and the consequence of the exposure differs depending on the substance used. Alcohol, tobacco, cannabis and opioids are among the most frequent used substances during pregnancy and offspring outcomes may include birth defects, developmental disability, fetal alcohol syndrome, childhood obesity, decreased birth weight, poor inhibitory control and other organ deficits [44]. Thus, many neuropsychiatric disorders appear to result from interactions among genetic background, the prenatal environment and postnatal lifestyle choices [45, 46]. Given the known association between deficits within the prenatal environment and other neuropsychiatric disorders it is plausible to suggest that the prenatal environment and subsequent gene expression may play a role in future cannabis use and/or CUD.

As previously mentioned, a variety of factors contribute to the complex etiology of neuropsychiatric disorders such as epigenetic modification. Epigenetic modifications that can regulate gene expression include DNA methylation, nucleosomal structure and positioning, post-translational modification of nucleosome histones, histone replacement and small RNA molecules that influence protein production [47]. The most studied form of epigenetic modification is DNA methylation, which can be influenced by a range of factors including genetic factors, disease, environmental exposures, and lifestyle. DNA methylation changes can be either persistent or reversible once the exposure is no longer present, adding value for biomarker development [48]. How cannabis, THC and other exogenous cannabis receptor modulators alter epigenetic mechanisms have been previously reviewed [47]. Relatively little is known about the molecular pathways influenced by cannabis, however, one study identified 13 proteins, 3 metabolites and 2 lipids significantly associated with a metabolite of THC and another found acute effects of cannabis or THC on the central nervous system and heart rate [49, 50]. In addition to DNA methylation, post-transcriptional chemical medication of RNA is rapidly emerging as a key role in regulating gene expression, known as epitranscriptomics [51]. Of growing interest within this field is N4-acetylcystidine (ac4C), a key role in the transcriptional translation process. ac4C has been implicated in the occurrence of various disease such as inflammation, metabolic diseases, autoimmune diseases, and cancer [52]. While the role ac4C may play in neuropsychiatric disorders remains unknown, it is
important to consider the role epitranscriptomics plays in the gene expression with normal development.

Current knowledge on cannabis has demonstrated that cannabis can induce structural changes to brain regions including the hippocampus, amygdala, cerebellum, prefrontal cortex and striatum as well as grey matter volume [53–55]. Potential pre-existing neurobiological factors may exist in cannabis use as well as gene x drug interactions. For instance, in young teens, reduced orbitofrontal cortex volume has been found to predict initiation of cannabis use in later adolescence. The G allele of rs2023239 of \textit{CNR1} is linked with higher cortical CB1R and is associated with smaller hippocampal volume in chronic cannabis users, but not healthy controls and findings that suggest only individuals with a high genetic risk of schizophrenia experience a negative impact on cortical maturation during early adolescence thus suggestive of gene x drug interactions [56–58]. In addition, functional MRI evidence suggest specific brain activity signatures with cannabis use such as increased functional connectivity associated with the default node network and insula networks and hippocampal and parahippocampal atrophy have been associated with chronic cannabis use [59, 60]. However, neuroimaging studies of cannabis users have yielded inconsistent findings and may reflect individual differences that preceded cannabis use. The inconsistent findings in the literature highlight the need for large longitudinal studies utilizing before-and-after cannabis use neuroimaging [61]. Taken together, it is plausible that structural differences in brain regions could be influenced by genetic differences between individuals, explaining the mixed evidence within neuroimaging. Further research is required to determine the complex interactions amongst individual genetic predispositions, prenatal environment, and postnatal environment contributing to individual cannabis use behaviour and/or the development of CUD. Understanding the genetic predispositions is one piece of the puzzle in understanding the complex development of cannabis use and CUD.

Finally, it is important to consider the shared genetic basis of other substance use disorders. Heritability estimates across substance use disorders vary, with heritability lowest for hallucinogens (0.39) and highest for cocaine use (0.72) [62, 63]. Additionally, substance use disorders are the result of gene x environment interactions, with partial risk inborn and another part determined by environmental experiences [62]. Previous reviews have summarized the literature on GWASs for various substance use disorders including alcohol use disorder, nicotine use disorder, CUD, OUD, and cocaine use disorder. However, genetic studies within specific substance use disorders have had varying success in replicating previously identified associations, limiting evidence for shared genetic basis across substance use disorders [63, 64]. The complexity of substance use disorder make genetic prediction efforts difficult, and while currently only alcohol use disorder have been genetically correlated with CUD, continued advancements in molecular genetic studies and substance use disorder at larges further our understanding of the biological pathways underlying substance use disorders [9, 63, 65]. For instance, \textit{CNR1} and \textit{CNR2}, components of the endocannabinoid system, are major targets of investigation for their impact in neuropsychiatry and addiction phenotypes suggested shared genetic risk factors [66, 67]. In regards to neuropsychiatric disorders, Mendelian randomization studies have found mixed evidence on the causal effect of cannabis initiation and schizophrenia, finding weak evidence that cannabis initiation increases schizophrenia risk and strong evidence that schizophrenia liability increases the odds of cannabis initiation, and causal evidence of ADHD on cannabis initiation [68–72]. Through continued advances, it is hoped that the underlying genetic basis for CUD, or a shared genetic basis for all substance use disorders, will be identified to provide preventative measures and treatment for substance use disorders in the future.

\textbf{Limitations}

While this systematic review was rigorous and involved a peer-reviewed protocol, it is not without limitations. First, our inclusion criteria limited our review to only GWASs, meaning any GWAS meta-analyses and candidate gene studies were excluded. GWAS meta-analyses and candidate gene studies are often more powered due to their larger sample sizes and minimal genetic variants tested, respectfully [11]. However, including only GWASs was decided a priori to capture novel genetic variants associated with cannabis use and avoid the inclusion of multiple studies which could use the same genetic dataset. Second, it is important to note that this review is susceptible to publication bias, as studies that do not achieve genome-wide significance may be less likely to be published, and thus, not included in this review. Unpublished GWAS findings may exist with SNPs reaching the borderline significance threshold. While we cannot eliminate publication bias entirely, we searched abstracts, GWAS catalogs, and databases for any near significant findings that were not published. If a relevant abstract was identified, without the full study published, the first author was contacted to determine whether the full GWAS had been published or was going to be submitted to a journal. Finally, if a study met our inclusion criteria but did not report any SNPs that fell below the genome-wide significance threshold, study authors were contacted to confirm if any SNPs had reached the borderline significant threshold.
set for this review. Third, due to the heterogeneity of the reported findings, it was not possible to conduct a meta-analysis or sex and ethnicity subgroup analyses. Although we could not conduct a meta-analysis, we qualitatively summarized the studies and reported a comprehensive list of all SNPs reaching the significance threshold for this study.

Conclusion
This systematic review was able to summarize GWAS findings within the field of cannabis use. The results can inform future candidate gene studies and GWASs of possible replicable SNPs that require further investigation. We were able to identify all GWASs conducted on cannabis use, highlighting the need for further research as no two GWASs reported the same SNP or gene associated with cannabis use. Further, included GWASs had limited ethnic diversity, with only European or African American participants. Recommendations are made for future research to replicate reported associations and include diverse ethnic populations to test whether SNPs associated with cannabis use reported are generalizable across study populations and if associations differ by ethnicity.

Abbreviations
GWAS: Genome-wide Association Study; CUD: Cannabis Use Disorder; GWASs: Genome-wide Association Studies; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; HuGENET: The Human Genome Epidemiology Network; PROSPERO: International Prospective Register of Systematic Reviews; DSM: Diagnostic and Statistical Manual; ICD-10: International Statistical Classification of Diseases and Related Health Problems -10; Q-Genie: The quality of genetic association studies; SAGE: Study of Addiction: Genetics and Environment; ICC: International Cannabis Consortium; ICGHD: International Consortium on the Genetics of Heroin Dependence; iPSYCH: Integrative Psychiatric Research; ADHD: Attention-Deficit Hyperactivity Disorder.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12920-021-01035-5.

Additional File 1. PRISMA 2009 checklist.

Acknowledgements
Not applicable.

Authors’ contributions
ZS is the guarantor. AH, CC, and ZS conceptualized the systematic review. AH implemented the design of the review and search strategy with the aid of CC, and SS. AH, CC, AD, MB, and RK screened studies, extracted data and assessed the quality of the studies. AH prepared the first draft, and the final manuscript was reviewed and revised by CC, AD, MB, RK, FK, LT, and ZS. All authors read and approved the final manuscript.

Funding
This systematic review was partially funded by CIHR (Grant number PJT-156306). The funding agency had no role in the study design, interpretation of data, or dissemination of results.

Availability of data and materials
All data generated or analysed during this study are included in this published article. Primary articles included in this systematic review can be found at the following links: https://onlinelibrary.wiley.com/doi/abs/10.1002/j.1369-1600.2010.00253.x. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037687/1613004766. https://www.nature.com/articles/s41593-019-04146-1. https://link.springer.com/article/10.1007/s10519-015-9723-9. https://www.nature.com/articles/s41593-018-0206-1?fbclid=IwAR20cNM7ZDBK7G7pQ7Nim521tkUCEcCYdTLQ5pQI9wemslbcnM_TMeAUTSg. https://jamanetwork.com/journal/jamapsychiatry/article-abstract/2504223.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare they have no competing interests.

Author details
1Neuroscience Graduate Program, Department of Psychiatry and Behavioural Neurosciences, McMaster University, 100 West 5th St., Hamilton, ON L8N 3K7, Canada. 2Health Science Library, McMaster University, 1280 Main St. W., Hamilton, ON L8S 4L8, Canada. 3Integrated Science Program, McMaster University, 1280 Main St. W., Hamilton, ON L8S 4L8, Canada. 4Michael G. DeGroote School of Medicine, McMaster University, 1280 Main St. W., Hamilton, ON L8S 4L8, Canada. 5Department of Health Research Method, Evidence and Impact, 1280 Main St. W., Hamilton, ON L8S 4L8, Canada.

Received: 31 March 2021 Accepted: 15 July 2021
Published online: 12 August 2021

References
1. Degenerhardt L, Charlton F, Ferrari A, Santomauro D, Erskine H, Mantilla-Herrera A, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5(12):987–1012.
2. Statistics Canada. National Cannabis Survey, forth quarter 2019. 2019.
3. Volkow ND, Baler RD, Compton WM, Weiss SRB. Adverse health effects of marijuana use. N Engl J Med. 2014;370(23):2219–27.
4. Sherva R, Wang Q, Kranzler H, Zhao H, Koesterer R, Herman A, et al. Genome-wide association study of cannabis dependence severity, novel risk variants, and shared genetic risks. JAMA Psychiat. 2016;73(5):472–80.
5. Bahj A, Stephenson C. International perspectives on the implications of cannabis legalization: a systematic review & thematic analysis. Int J Environ Res Public Health. 2019;16(7):3095.
6. Verweij KJH, Zietsch BP, Lynskey MT, Medland SE, Neale MC, Martin NG, et al. Genetic and environmental influences on cannabis use initiation and problematic use: a meta-analysis of twin studies. Addiction. 2010;105(3):417–30.
7. Agrawal A, Chou VL, Carey CE, Baranger DAA, Zhang B, Sherva R, et al. Genome-wide association study identifies a novel locus for cannabis dependence. Mol Psychiatry. 2018;23(5):1293–302.
8. Minicic CC, Verweij KJH, Most PJ, Mbaarek H, Bernard M, Eijk KR, et al. Genome-wide association meta-analysis of age at first cannabis use. Addiction. 2018;113(11):2073–86.
9. Pasman JA, Verweij KJH, Gerring Z, Stringer S, Sanchez-Roige S, Treur JL, et al. GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia. Nat Neurosci. 2018;21(9):1161–70. https://doi.org/10.1038/s41593-018-0206-1.
10. Stringer S, Minicic CC, Verweij KJH, Mbaarek H, Bernard M, Derringer J, et al. Genome-wide association study of lifetime cannabis use based on a large
meta-analytic sample of 32,330 subjects from the International Cannabis Consortium. Transl Psychiatry. 2016;6(3):e769.
11. Tam V, Patel N, Turcotte M, Bossé Y, Paré G, Meaney D. Benefits and limitations of genome-wide association studies. Nat Rev Genet. 2019;20:687–94.
12. The Government of Canada. Cannabis Health Effects. 2019.
13. Hall W. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? Addiction. 2015;110(1):19–35.
14. Gobbi G, Atkin T, Zytynski T, Wang S, Askari S, Boruff J, et al. Association of cannabis use in adolescence and risk of depression, anxiety, and suicidal ideation in young adulthood: a systematic review and meta-analysis. JAMA Psychiat. 2019;76(4):426–34.
15. Moher D, Liberati A, Tetzlaff J, Altman D, Group P. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097.
16. Little J, Higgins JPT, Bray M, Ioannidis J, Khoury M, Manolio T, et al. The HuGENetTM HuGE review handbook, version 1.0. Ottawa, Ontario, Canada HuGeNet Canada Coord Cent. 2006.
17. Hillmer A, Chawar C, D’Elia A, Kapoor R, Butt M, Samaan Z. A systematic review and meta-analysis of genome-wide association studies and cannabis use. PROSPERO: International prospective register of systematic reviews. 2020.
18. Hillmer A, Chawar C, Sanger S, D’Elia A, Butt M, Kapoor R, et al. Genetic determinants of cannabis use: a systematic review protocol. Syst Rev. 2020;9(1):1–6.
19. National Academies of Sciences Engineering and Medicine. The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research [Internet]. Washington, DC: National Academies Press; 2017. Available from: https://www.ncbi.nlm.nih.gov/books/NBK423845/
20. Veritas Health Innovation. Covidence systematic review software [Internet]. Melbourne, Australia. Available from: https://www.covidence.org/
21. Dudbridge F, Gusnanto A. Estimation of significance thresholds for genomewide association scans. Genet Epidemiol Off Publ Int Genet Epidemiol Soc. 2008;32(3):227–34.
22. SohaniZN, Meyer D, de Souza RJ, Joseph PG, Gandhi M, Dennis BB, et al. Assessing the quality of published genetic association studies in meta-analyses: The quality of genetic studies (Q-Genie) tool. BMC Genet. 2015;16:14.
23. Guyatt GH, Oxman AD, Schünemann H, Tugwell P. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology: J Clin Epidemiol. 2011;64(4):380–2.
24. Foroutan F, Guyatt G, Zuk V, Vandvik PO, Alba AC, Mustafa R, et al. GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks. J Clin Epidemiol. 2020;121:62–70.
25. Center for History New Media. Zotero: The Next-Generation Research Tool [Internet]. Use George Mason University; 2009. Available from: http://www.zotero.org/。“
26. Agrawal A, Lynskey MT, Hinrichs A, Grucza R, Saxone SF, Krueger R, et al. A genome-wide association study of DSM-IV cannabis dependence. Addict Biol. 2011;16(3):514–8.
27. Demontis D, Rajagopal VM, Thorgeirsson TE, Als TD, Grove J, Leppälä K, et al. Genome-wide association study implicates CHRNA2 in cannabis use disorder. Nat Neurosci. 2019;22(7):1066.
28. Agrawal A, Lynskey MT, Bucholz KK, Kapoor M, Almasy L, Dick DM, et al. DSM-5 cannabis use disorder: a phenotypic and genomic perspective. Drug Alcohol Depend. 2014;134(1):362–9. https://doi.org/10.1016/j.drugalcdep.2013.11.008.
29. Minicà CC, Dolan CV, Hottenga J-J, Alis TD, Grove J, Mbarek H, et al. Haplotype, SNP-and gene-based analyses of cannabis use initiation and age at onset. Behav Genet. 2015;45(5):503–13.
30. Ziyatdinov A, Kim J, Prokopenko D, Privé F, Laporte F, Loh P-R, et al. Estimating the effective sample size in association studies of quantitative traits. bioRxiv. 2019;
31. Berthea (MD): National Library of Medicine (US) National Centre for Bioinformatics Information. dbGEnet [Internet]. 2004. Available from: https://www.ncbi.nlm.nih.gov/gene/。“
32. UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 2019;47(D1):DS05–15.
33. Yates AD, Achuthan P, Akkanni W, Allen J, Allen J, Alvarez-Jarreta J, et al. Ensembl 2020. Nucleic Acids Res. 2020;48(D1):D682–8.
34. Wu Y, Cao H, Baranova A, Huang H, Li S, Cai L, et al. Multi-trait analysis for genome-wide association study of five psychiatric disorders. Transl Psychiatry. 2020;10(1):1–11.
35. Johnson EC, Demontis D, Thorgeirsson TE, Walters RK, Polimanti R, Hatoum AS, et al. A large-scale genome-wide association study meta-analysis of cannabis use disorder. Lancet Psychiatry. 2020;7(12):1032–45.
36. Taylor M, Cousijn J, Filbey F. Determining risks for cannabis use disorder in the face of changing legal policies. Curr Addict Rep. 2019;6(4):466–77.
37. Yan X, Zhao X, Li J, He L, Xu M. Effects of early-life maltreatment on neuromodulation and neurophysiological disorders and the potential mechanisms. Prog Neuro-Psychopharmacol Biol Psychiatry. 2018;83:64–75.
38. Wang X, Jiao X, Xu M, Wang B, Li J, Yang F, et al. Effects of circulating vitamin D concentrations on emotion, behavior and attention: a cross-sectional study in preschool children with follow-up behavior experiments in juvenile mice. J Affect Disord. 2020;275:290–8.
39. Chen J, Zhao X, Cui L, He G, Wang X, Wang F, et al. Genetic regulatory subnetworks and key regulating genes in rat hippocampus perturbed by prenatal malnutrition: implications for major brain disorders. Aging (Albany NY). 2020;12(9):8343.
40. Xu M-Q, Sun W-S, Liu B-K, Feng G-Y, Yu L, Yang L, et al. Prenatal malnutrition and adult schizophrenia further evidence from the 1959–1961 Chinese famine. Schizophr Bull. 2009;35(3):568–76.
41. Oberlander VC, Xu X, Chini M, Hanganu-Opatz IL. Developmental dysfunction of prefrontal–hippocampal networks in mouse models of mental illness. Eur J Neurosci. 2019;50(6):3072–84.
42. Aizer A, Stroud L, Buka S. Maternal stress and child outcomes: Evidence from siblings. J Hum Resour. 2016;51(3):523–55.
43. DiPietro JA. Maternal stress in pregnancy: considerations for fetal development. J Adolesc Heal. 2015;62(5):53–8.
44. Chang G. Maternal substance use consequences, identification, and interventions. Alcohol Res. 2020;40(2):6.
45. Newhamp JM, Moss TM, Nitsos I, Sloboda DM, Challs JRG. Nutrition and the early origins of adult disease. Asia Pac J Clin Nutr. 2002;11:537–42.
46. Taylor PD, Poston L. Developmental programming of obesity in mammals. Exp Physiol. 2007;92(2):287–98.
47. Szutorisz H, Hurd YL. Epigenetic effects of cannabis exposure. Biol Psychiatry. 2016;79(7):586–94.
48. Markunas CA, Hancock DB, Xu Z, Quach BC, Fang F, Sandler DP, et al. Epigenome-wide analysis uncovers a blood-based DNA methylation biomarker of lifetime cannabis use. Am J Med Genet Part B Neuropsychiatr Genet. 2021;186(3):173–82.
49. Hinckley JD, Saba L, Raymond K, Bartels K, Klawitter J, Christians U, et al. An approach to biomarker discovery of cannabis use utilizing proteomic, metabolomic, and lipidomic analyses. Cannabis Cannabinoid Res. 2020;5:105–17.
50. Zuurman L, Ippel AE, Moin E, Van Gerven JMA. Biomarkers for the effects of cannabis and THC in healthy volunteers. Br J Clin Pharmacol. 2009;67(1):5–21.
51. Karthiya R, Wasli SM, Kandellia P. Emerging role of 4N-acetylcysteine modification of RNA in gene regulation and cellular functions. Mol Biol Rep. 2020;47(1):1–11.
52. Jin G, Xu M, Zou M, Duan S. The processing, gene regulation, biological functions, and clinical relevance of N4-acetylcysteine on RNA: a systematic review. Mol Ther. 2020;28:13–24.
53. Battistella G, Fornari E, Akanni W, Chintou H, Dao K, Fabritius M, et al. Long-term effects of cannabis on brain structure. Neuropsychopharmacology. 2014;39(9):2041–8.
54. Scheffer F, Du Plessis S, Asmal L, Kilian S, Phahadira L, Luckhoff HK, et al. Cannabis use and hippocampal subfield volumes in males with a first episode of a schizophrenia spectrum disorder and healthy controls. Schizophr Res. 2021;231:13–21.
55. Batalla A, Bhattacharyya S, Yuecel M, Fusic-Poli P, Crippa JA, Nogue S, et al. Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PLoS ONE. 2013;8(2):e55821.
56. Schacht JP, Hutchison KE, Filbey FM. Associations between cannabinoid receptor-1 (CNR1) variation and hippocampus and amygdala volumes in heavy cannabis users. Neuropsychopharmacology. 2012;37(11):2368–76.
57. French L, Gray C, Leonard G, Perron M, Pike GB, Richer L, et al. Early cannabis use, polygenic risk score for schizophrenia and brain maturation in adolescence. JAMA Psychiat. 2015;72(10):1002–11.

58. Cheetham A, Allen NB, Whittle S, Simmons JG, Yucel M, Lubman DI. Orbitofrontal volumes in early adolescence predict initiation of cannabis use: a 4-year longitudinal and prospective study. Biol Psychiatry. 2012;71(8):684–92.

59. Bloomfield MAP, Hindocha C, Green SF, Wall MB, Lees R, Pettrilli K, et al. The neuropsychopharmacology of cannabis: a review of human imaging studies. Pharmacol Ther. 2019;195:132–61.

60. Ferland J-MN, Hurd YL. Deconstructing the neurobiology of cannabis use disorder. Nat Neurosci. 2020;23(5):600–10.

61. Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiat. 2016;73(3):292–7.

62. Ducci F, Goldman D. The genetic basis of addictive disorders. Psychiatr Clin. 2012;35(2):495–519.

63. Deak JD, Johnson EC. Genetics of substance use disorders: a review. Psychol Med. 2021;1–12.

64. Prom-Wormley EC, Ebejer J, Dick DM, Bowers MS. The genetic epidemiology of substance use disorder: a review. Drug Alcohol Depend. 2017;180:241–59.

65. Zhou H, Sealock JM, Sanchez-Roige S, Clarke T-K, Levey DF, Cheng Z, et al. Genome-wide meta-analysis of problematic alcohol use in 435,563 individuals yields insights into biology and relationships with other traits. Nat Neurosci. 2020;23(7):809–18.

66. Onalvi ES, Ishiguro H, Sgro S, Leonard CM. Cannabinoid receptor gene variations in drug addiction and neuropsychiatric disorders. J Drug Alcohol Res. 2013;2(1):1–11.

67. Marco EM, García-Gutiérrez MS, Bermúdez-Silva F-J, Moreira F, Guimarães F, Manzanares J, et al. Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. Front Behav Neurosci. 2011;5:63.

68. Gage SH, Jones HJ, Burgess S, Bowden J, Davey Smith G, Zammit S, et al. Assessing causality in associations between cannabis use and schizophrenia risk: a two-sample Mendelian randomization study. Psychol Med. 2017;47(5):971–80.

69. Vaucher J, Keating BJ, Lasserre AM, Gan W, Lyall DM, Ward J, et al. Cannabis use and risk of schizophrenia: a Mendelian randomization study. Mol Psychiatry. 2018;23(5):1287–92.

70. Johnson EC, Hatoum AS, Deak JD, Polimanti R, Murray RM, Edenberg HJ, et al. The relationship between cannabis and schizophrenia: a genetically informed perspective. Addiction. 2021;

71. Treur JL, Demontis D, Smith GD, Sallis H, Richardson TG, Wiers RW, et al. Investigating causality between liability to ADHD and substance use, and liability to substance use and ADHD risk, using Mendelian randomization. Addict Biol. 2021;26(1):e12849.

72. Artigas MS, Sánchez-Mora C, Rovira P, Richarte V, Garcia-Martínez I, Pagerols M, et al. Attention-deficit/hyperactivity disorder and lifetime cannabis use: genetic overlap and causality. Mol Psychiatry. 2020;25(10):2493–503.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.